Full Press Release Details
Participate at Upcoming Institutional Investor Conferences
N.J., March 11, 2021 -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company
focused on the discovery, development, and commercialization of drugs for the treatment of cancer, today announced that James Caruso,
president and CEO, will present a company overview and be available for 1x1 meetings at the following upcoming conferences:
31st Annual Healthcare Conference
| Date : | March 16, 2021 |
| Presentation Time: | 8:00 am ET |
| Available for 1x1 meetings | |
| Webcast: | To register, click on the link HERE |
2021 Emerging Growth Virtual Conference
| Date: | March 17-19, 2021 |
| Webcast: | To register, click on the link HERE |
presentation is available for on-demand viewing in the link HERE.
Cellectar Biosciences
is focused on the discovery, development and commercialization of drugs for the treatment of cancer. The company is developing
proprietary drugs independently and through research and development collaborations. The company's core objective is to leverage
its proprietary Phospholipid Drug Conjugate (PDC) delivery platform to develop PDCs that specifically target cancer cells,
delivering improved efficacy and better safety as a result of fewer off-target effects. The company's PDC platform possesses
the potential for the discovery and development of the next-generation of cancer-targeting treatments, and it plans to develop
PDCs independently and through research and development collaborations.
product pipeline includes CLR 131, a small-molecule PDC designed to provide targeted delivery of iodine-131 (radioisotope), and
proprietary preclinical PDC chemotherapeutic programs and multiple partnered PDC assets.
For more information,
please visit www.cellectar.com or join the conversation by liking and following us on
the company's social media channels: Twitter, LinkedIn,